



17 December 2018

ASX Announcement

Race agreement with TrueMed for Bisantrene NPP in Israel

HIGHLIGHTS

- **NPP distribution agreement with TrueMed in Israel**
- **Profit share agreement based on sales of Bisantrene**

17 December 2018: Race Oncology Limited (RAC.AX) is very pleased to announce that it has signed an agreement with Israel-based TrueMed Ltd for distribution and sales of Bisantrene in Israel, under a named patient program (NPP)¹.

TrueMed is a pharmaceutical distributor with experience in driving NPPs in Israel.

“We believe that Israel could be an important contributor to future global NPP sales of Bisantrene,” said Race CEO, Peter Molloy. “TrueMed has a unique approach and expertise in NPP, along with a firm belief in the opportunity for Bisantrene in AML, based on their own market research.”

According to TrueMed’s owners and co-CEOs, Shmulik Berkovich and Arie Koren, “TrueMed is proud to partner with Race Oncology to provide access to Bisantrene for patients who need it. Bisantrene’s long and robust development program makes it a potential game-changer and a significant option for those patients deemed appropriate by their treating physicians.”

Under the distribution agreement, Race and TrueMed will share the value of all Bisantrene NPP sales in Israel, with 60% of sales turnover paid to Race and 40% retained by TrueMed.

TrueMed will have the exclusive right to sell and distribute Bisantrene in Israel for NPP use and will source Bisantrene exclusively from Race’s global distribution partner Durbin, in the UK. TrueMed will be responsible for gaining the approval of the Israeli Ministry of Health (IMOH) for local NPP distribution of Bisantrene; sales cannot commence until that approval has been obtained. The agreement will operate for an initial period of three years, after which, it can be terminated with nine months’ notice by either party.

¹ A named patient program (NPP) enables the supply of unapproved medicines to patients with life-threatening diseases.

About TrueMed

TrueMed is a prominent rare disease and specialty care company in Israel, providing a complete local distribution and marketing solution for pharmaceutical partners with unique therapies in specific therapeutic areas. TrueMed stands out in the local market as an innovative company and the partner of choice for innovators with cutting-edge therapies such as Sarepta, Amicus, Lucane, AOP Orphan and other (<http://www.truemedtx.com>).

About Race Oncology (RAC.ASX)

Race Oncology is a specialty pharmaceutical company whose business model is to pursue later-stage drug assets in the cancer field that have been overlooked by big pharma. The company's first asset is Bisantrone, a chemotherapy drug, which was the subject of more than 40 clinical studies during the 1980s and 1990s before the drug was abandoned after the results of a Phase III breast cancer study and a series of pharmaceutical mergers. Bisantrone has compelling Phase II data in acute myeloid leukaemia (AML) and Race is seeking to gain US FDA approval for Bisantrone for AML under the accelerated 505(b)(2) regulatory pathway. Bisantrone is the subject of two recently granted US patents and has been awarded US Orphan Drug designation, along with a Rare Paediatric Disease designation.

Media contact:

Heidi Cuthbert

+61 411 272 366

E: heidi.cuthbert@multiplier.com.au